The following is a sample from a larger document.
This section is for: Expert Witness Landscape
The section is from a Focused Issue Brief on: Assessing Scientific Causation Claims in PFAS Exposure Litigation
The primary research jurisdiction is: United States of America
[Back]
Expert Witness Landscape
The expert witness pool for PFAS causation disputes draws from toxicology, epidemiology, environmental chemistry, and public health — fields where the same names appear repeatedly across different cases and regulatory proceedings. These experts have built their reputations during the evolution of PFAS science over the past two decades, meaning their documented positions often reflect the trajectory of scientific understanding rather than fixed viewpoints. However, patterns of testimony, funding relationships, and methodological approaches create predictable alignments that matter for litigation planning.
Core Toxicology Experts
Dr. Jamie DeWitt at East Carolina University is among the most frequently cited toxicologists on PFAS health effects. Her research focuses on immunotoxicity — how PFAS compounds affect immune system function. DeWitt has testified in multiple state-level PFAS cases since 2018, consistently arguing that animal studies showing immune suppression translate to human health risks at environmentally relevant exposure levels. Her position relies heavily on mechanistic data showing PFAS interference with immune cell development and function. In litigation including State of New Hampshire v. 3M (2019), her testimony addressed potential links between PFAS exposure and immune-related health outcomes. DeWitt has been challenged on extrapolation from animal studies to human populations and on her interpretation of epidemiological data showing inconsistent immune effects across different exposed populations.
DeWitt’s funding comes primarily from federal sources — NIH and EPA grants — with documented opposition to industry-funded research on methodological grounds. She has publicly criticized studies funded by chemical manufacturers as structurally biased, creating a clear position against industry science that extends beyond specific study findings. This creates both strength and vulnerability: credibility with juries skeptical of industry influence, but exposure to challenges about predetermined conclusions.
Dr. Linda Birnbaum, former director of the National Institute of Environmental Health Sciences and current independent consultant, carries significant regulatory credibility but limited direct PFAS testimony experience. Birnbaum oversaw federal PFAS research policy from 2009 to 2019 and has consistently argued that regulatory agencies have been too conservative in setting exposure limits. Her documented position treats PFAS as presumptively harmful based on persistence and bioaccumulation, arguing that the burden should be on manufacturers to prove safety rather than on regulators to prove harm.
Birnbaum testified in City of Stuart v. DuPont (2021) that EPA’s advisory levels for PFOA and PFOS were inadequate to protect public health. Her testimony emphasized the “essential irreversibility” of PFAS exposure due to environmental persistence and extremely long biological half-lives. Cross-examination focused on the gap between her regulatory policy positions and the epidemiological evidence for specific health outcomes, particularly her willingness to infer causation from mechanistic plausibility rather than demonstrated human effects.
Dr. Christopher Lau at EPA’s National Health and Environmental Effects Research Laboratory has extensive PFAS research experience but limited litigation testimony. Lau’s documented position emphasizes developmental toxicity, particularly effects on fetal growth and development. His research shows PFAS crossing the placental barrier and affecting fetal development in animal models. When he has testified — primarily in regulatory proceedings rather than litigation — Lau has been conservative about extrapolating from animal studies to human health claims, requiring epidemiological confirmation for causal assertions.
This conservative approach makes Lau potentially valuable for either side depending on the specific causation claim. His testimony tends to support biological plausibility arguments while requiring stronger epidemiological evidence than other toxicologists for definitive causal conclusions.
Epidemiology Specialists
Dr. Kyle Steenland at Emory University has become the dominant epidemiological expert in PFAS litigation, testifying in multiple major cases since 2015. Steenland played a leading role in the C8 Health Project — one of the largest epidemiological studies of a PFAS-exposed population — which followed residents near DuPont’s Washington Works facility in West Virginia. This study documented associations between PFOA exposure and kidney cancer, testicular cancer, thyroid disease, pregnancy-induced hypertension, and ulcerative colitis.
Steenland’s testimony consistently relies on the C8 findings as the strongest evidence for PFAS causation in humans. He argues that the study’s size, exposure range, and follow-up period provide compelling evidence for causal relationships. In In re DuPont C-8 Personal Injury Litigation (2015-2017), his testimony supported causation claims for all five diseases identified in the C8 study. Steenland has been challenged on the generalizability of C8 findings to other PFAS compounds and exposure scenarios, the study’s observational design limitations, and inconsistencies with other epidemiological studies showing weaker or absent associations.
Steenland acknowledges that epidemiological evidence for most PFAS health effects remains limited outside the C8 study population. However, he has argued that the biological similarity between different PFAS compounds supports extending C8 findings to other exposures. This extrapolation argument represents his most vulnerable testimony position, particularly when addressing PFAS compounds with different chemical properties or populations with different exposure patterns.
Dr. Philippe Grandjean at Harvard School of Public Health focuses on developmental and immunological effects of PFAS exposure. Grandjean’s research emphasizes effects in children, particularly reduced vaccine efficacy and developmental delays. His testimony typically argues that children represent the most vulnerable population for PFAS effects and that even low-level exposures during critical developmental windows can cause permanent harm.
Grandjean testified in State of Minnesota v. 3M (2018) that PFAS exposure reduced vaccine effectiveness in children, supporting claims for medical monitoring and population health impacts. His position relies heavily on studies from the Faroe Islands and Denmark showing associations between PFAS exposure and reduced antibody responses to childhood vaccines. Cross-examination has challenged the applicability of these studies to U.S. populations with different exposure sources, genetic backgrounds, and healthcare systems.
Grandjean’s documented funding includes both federal grants and environmental advocacy organizations, which creates some vulnerability to industry challenges about bias. However, his pediatric focus and international research scope provide perspectives that purely industry-funded experts cannot easily dismiss.
Dr. Margaret Karagas at Dartmouth has emerging prominence in PFAS epidemiology through her work on cancer endpoints. Karagas has testified in three cases since 2020, focusing on kidney and liver cancer associations with PFAS exposure. Her testimony emphasizes mechanistic plausibility — PFAS effects on cellular metabolism and DNA repair — combined with epidemiological evidence for cancer increases in highly exposed populations.
Karagas represents a more cautious epidemiological approach than Steenland, requiring stronger evidence for causal conclusions and acknowledging significant uncertainty in current data. This positioning makes her potentially valuable for defendants in cases involving health effects with weaker epidemiological support, but limits her utility for plaintiffs seeking broad causal claims.
Industry-Affiliated Experts
Dr. Geary Olsen retired from DuPont after leading the company’s PFAS health research program for over two decades. Olsen authored many of the foundational studies on PFAS worker exposure and has testified extensively for chemical manufacturers since 2010. His consistent position argues that epidemiological evidence for PFAS health effects remains inadequate for causal conclusions, emphasizing study limitations, confounding variables, and inconsistent findings across different populations.
Olsen’s testimony relies heavily on methodological critique rather than alternative causal theories. In Hardwick v. 3M (2019), his testimony challenged epidemiological studies on kidney cancer by highlighting exposure measurement limitations, selection bias, and failure to control for occupational co-exposures. Olsen argues that apparent PFAS health associations reflect study artifacts rather than true causal relationships.
Olsen’s industry employment history creates obvious challenges but also provides unique expertise in occupational exposure scenarios that academic experts often lack. His detailed knowledge of workplace exposure levels and industrial processes can effectively challenge exposure estimates and highlight gaps in plaintiff causation theories. However, his credibility with juries may be limited by his long industry affiliation.
Dr. Julie Goodman at Gradient Corporation has testified for chemical manufacturers in multiple PFAS cases since 2016. Goodman specializes in regulatory toxicology and risk assessment, arguing that current exposure levels fall below thresholds for adverse health effects. Her testimony typically emphasizes the gap between animal study findings and human health risks, challenging dose-response extrapolations and questioning the relevance of high-dose animal studies to environmental exposure scenarios.
Goodman’s approach focuses on regulatory and risk assessment frameworks rather than challenging the underlying science directly. She argues that existing regulatory processes adequately account for PFAS risks and that litigation claims seek to bypass established scientific review procedures. In City of Oakdale v. 3M (2020), her testimony argued that EPA advisory levels for PFAS already incorporate appropriate safety factors and that additional health-protective measures were unnecessary.
Goodman’s consulting firm relationship with industry creates credibility challenges, but her regulatory expertise provides technical knowledge that academic experts may lack. Her testimony tends to be most effective when challenging risk assessment methodologies rather than disputing basic toxicological findings.
Dr. Gary Ginsberg at the Connecticut Department of Public Health represents an unusual position in the expert landscape — state government experience with regulatory independence from industry. Ginsberg has developed PFAS health advisories for Connecticut and testified in regulatory proceedings supporting stronger protective standards. His documented position treats PFAS as emerging contaminants requiring precautionary regulatory approaches.
Ginsberg’s testimony emphasizes the regulatory inadequacy argument — that existing standards fail to protect public health based on current scientific understanding. However, he has not testified extensively in litigation contexts, limiting the available record of how his positions translate to legal causation standards rather than regulatory policy decisions.
Methodological Critics and Statisticians
Dr. Michael Dourson at the University of Cincinnati has emerged as a key industry witness challenging epidemiological methodology in PFAS cases. Dourson’s testimony focuses on statistical analysis and study design rather than toxicological mechanisms, arguing that apparent PFAS health associations reflect analytical artifacts, publication bias, and inadequate control for confounding variables.
In litigation including 3M v. State of Minnesota (2018), Dourson criticized meta-analyses supporting PFAS health effects, arguing that they did not adequately account for study quality differences and potential bias. His approach emphasizes the weakness of observational epidemiology for causal inference and argues that experimental evidence remains inadequate to support legal causation claims.
Dourson’s methodology-focused approach can effectively challenge epidemiological testimony without requiring alternative causal theories. However, his previous industry consulting relationships and regulatory positions during the Trump administration create vulnerability to bias challenges that may limit jury credibility.
Environmental Chemistry and Exposure Assessment
Dr. Jennifer Field at Oregon State University has become a leading expert on PFAS environmental fate and transport. Field’s research documents PFAS persistence, mobility, and bioaccumulation in environmental systems. She has testified in multiple cases about exposure pathway reconstruction and environmental contamination extent.
Field’s testimony typically supports claims about environmental contamination scope and persistence but remains neutral on health effects causation. Her documented position treats PFAS environmental contamination as essentially permanent due to chemical persistence and mobility, supporting arguments about remediation necessity and ongoing exposure risks.
Field’s environmental chemistry expertise provides crucial foundation for exposure assessment but does not extend to health effects interpretation. Her testimony tends to strengthen plaintiff arguments about contamination extent while remaining vulnerable to challenges about exposure-to-dose relationships and the health significance of detected environmental levels.
Dr. Rainer Lohmann at the University of Rhode Island focuses on PFAS analytical chemistry and exposure measurement. Lohmann has testified about detection methodologies, laboratory capabilities, and measurement uncertainty in PFAS exposure assessment. His documented position emphasizes the technical challenges in accurate PFAS measurement and the limitations of available analytical methods.
Lohmann’s testimony can cut either direction depending on whether measurement uncertainty supports or undermines exposure claims in specific cases. His expertise provides technical foundation for challenging exposure estimates but may also support arguments about widespread contamination that existing monitoring has failed to detect.
Pattern Analysis and Testimony Trends
Several patterns emerge from the documented testimony history. Academic experts with federal funding tend to support broader causal claims while acknowledging scientific uncertainty. Industry-affiliated experts focus on methodological critique and regulatory adequacy rather than alternative causal theories. Government experts occupy middle ground, supporting regulatory precaution while requiring stronger evidence for legal causation.
Successful challenges to expert testimony have focused on extrapolation issues — from animal studies to human health, from occupational to environmental exposures, and from specific studied populations to general causation claims. Experts who acknowledge study limitations while maintaining causal conclusions tend to survive Daubert challenges more effectively than those who overstate certainty.
The expert pool remains relatively small, meaning the same experts appear across multiple cases with evolving positions as new research emerges. This creates opportunities for impeachment based on prior testimony but also reflects genuine scientific development rather than inconsistent advocacy.
Recent testimony shows increasing sophistication in addressing causation standards specifically rather than treating litigation as an extension of regulatory or academic debate. Experts who understand legal causation requirements and frame their testimony accordingly demonstrate greater effectiveness than those who simply present their research findings without legal context.
The available record indicates that PFAS expert testimony has faced methodological challenges from opposing parties regardless of substantive position. The evolving nature of PFAS science means that confident causal claims from any perspective face significant scrutiny, creating opportunities for effective cross-examination focused on scientific uncertainty rather than expert credibility alone.
[Back]